Press Releases Inventiva

Equities

IVA

FR0013233012

Market Closed - Euronext Paris Other stock markets 11:26:08 2024-06-11 am EDT			5-day change	1st Jan Change
3.135 ^EUR	-2.94%		-4.42%	-23.44%

May. 24	Inventiva: UBS Group sells its stake	CF
May. 22	Inventiva: share price falls, cash flow concerns	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Inventiva : 14. Brochure General Assembly 06 20 2024	May. 30	PU
Inventiva : 7. Special Report of the Board of Directors on Bonus Share Issues – AGA 2023 – 25 03 2024	May. 30	PU
Inventiva : 1. Agenda of Ordinary and Extraordinary General Meeting – 06 20 2024	May. 30	PU
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents	May. 30	GL
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents	May. 30	AQ
Inventiva : Franchissement de seuil	May. 27	PU
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024	May. 22	GL
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update	May. 21	GL
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH	May. 16	GL
Inventiva : Notice of meeting to the Ordinary and Extraordinary General Meeting dated June 20, 2024 - Form 6-K	May. 13	PU
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor	May. 13	GL
Inventiva : Présentation corporate avril 2024	Apr. 30	PU
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F	Apr. 03	GL
Inventiva announces the nomination of Andre Turenne as Director	Mar. 28	GL
Inventiva reports its 2023 full-year results	Mar. 27	GL
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results	Mar. 22	GL
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D	Mar. 18	GL
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D	Mar. 18	AQ
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D	Mar. 13	GL
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D	Mar. 13	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Inventiva

Equities

IVA

FR0013233012

Press Releases

Filters